ResMed (RMD) Stock Forecast & Price Target

Q: What analysts cover ResMed?

ResMed has been rated by research analysts at Citigroup , Jefferies Financial Group , KeyCorp , Mizuho , Morgan Stanley , Piper Sandler , Robert W. Baird , Rothschild & Co Redburn , Royal Bank Of Canada , The Goldman Sachs Group , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$221.49 -6.86 (-3.00%)

As of 12:27 PM Eastern

Compare

ResMed - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 16 Analyst Ratings

Sell
0

Hold
10

Buy
6

Based on 16 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Hold." Out of the 16 analysts, 10 have given a hold rating, and 6 have given a buy rating for RMD.

Consensus Price Target

$240.31
8.49% Upside

According to the 16 analysts' twelve-month price targets for ResMed, the average price target is $240.31. The highest price target for RMD is $300.00, while the lowest price target for RMD is $213.00. The average price target represents a forecasted upside of 8.49% from the current price of $221.49.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for RMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ResMed and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RMD Analyst Ratings Over Time

Type	Current Forecast 9/8/25 to 9/8/26	1 Month Ago 8/9/25 to 8/9/26	3 Months Ago 6/10/25 to 6/10/26	1 Year Ago 9/8/24 to 9/8/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	6 Buy rating(s)	7 Buy rating(s)	9 Buy rating(s)	11 Buy rating(s)
Hold	10 Hold rating(s)	9 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$240.31	$240.17	$286.18	$278.36
Forecasted Upside	8.49% Upside	13.37% Upside	47.68% Upside	-0.37% Downside
Consensus Rating	Hold	Hold	Moderate Buy	Moderate Buy

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ResMed Stock vs. The Competition

Type	ResMed	Healthcare Companies	Broader Market
Consensus Rating Score	2.38	2.30	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	8.66% Upside	890.85% Upside	14.82% Upside
News Sentiment Rating	Positive News See Recent RMD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/31/2026	KeyCorp 2 of 5 stars	Brett Fishbin 1 of 5 stars	Boost Target	Overweight	$255.00 ➝ $267.00	+11.03%
8/19/2026	Rothschild & Co Redburn 4 of 5 stars	Jackson Philips Not Rated	Initiated Coverage	Neutral	$230.00	+4.42%
8/11/2026	Weiss Ratings 5 of 5 stars		Upgrade	Hold (C-) ➝ Hold (C)
8/7/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$213.00	-1.07%
8/7/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Craig Wong-Pan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Perform	$234.00 ➝ $244.00	+15.18%
8/7/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Adam Maeder Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$233.00 ➝ $225.00	+7.36%
8/7/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Nathan Treybeck Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$225.00 ➝ $215.00	+1.80%
7/21/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$300.00	+53.10%
7/15/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$235.00 ➝ $220.00	+12.30%
7/12/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Laura Sutcliffe Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$270.00 ➝ $235.00	+15.10%
Get the Latest News and Ratings for RMD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.
7/10/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$240.00 ➝ $225.00	+9.78%
7/1/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
6/17/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Bailey Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$286.00 ➝ $230.00	+18.48%
4/15/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Low Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Overweight
4/13/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Outperform	$255.00	+11.52%
1/30/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jonathan Block Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$260.00 ➝ $265.00	+2.78%
9/2/2025	CLSA Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Outperform
8/1/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
1/31/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold
9/26/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$240.00 ➝ $270.00	+11.12%
9/18/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Peer Perform ➝ Underperform	$180.00	-28.25%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:17 PM ET.

Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, September 6, 2026. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

Here are some ways that investors could benefit from investing in ResMed Inc.:

ResMed Inc. recently announced a $450 million accelerated share repurchase agreement on August 31, 2026, which signals management's confidence in the company's long-term value and provides a direct mechanism to reduce the number of outstanding shares, potentially increasing earnings per share for remaining holders.
The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $2.95, which exceeded the analyst consensus estimate of $2.89, while also achieving a net margin of 26.94% and a return on equity of 25.58%, indicating efficient capital deployment and robust profitability.
ResMed Inc. recently increased its quarterly dividend to $0.66 per share, representing a boost from the previous $0.60 payout, which translates to an annualized dividend yield of approximately 1.2% and offers investors a growing income stream alongside potential capital appreciation.
With a current stock price of $228.25, the shares are trading below the average analyst price target of $240.31, suggesting that the market may be undervaluing the company relative to sell-side expectations, which could present an opportunity for price appreciation as the stock converges with these targets.
The company maintains a conservative balance sheet with a debt-to-equity ratio of only 0.06 and a current ratio of 3.10, providing significant financial flexibility to navigate economic uncertainties and fund future growth initiatives without relying heavily on external debt financing.

ResMed
Bear Case

Investors should be bearish about investing in ResMed Inc. for these reasons:

Pomerantz LLP is currently investigating claims on behalf of investors of ResMed Inc., as reported in September 2026, which introduces legal risk and potential distraction for management, as well as the possibility of financial liabilities or reputational damage that could negatively impact the stock price.
The consensus rating from seventeen research firms covering the company is currently "Hold," with ten analysts issuing hold ratings and seven issuing buy ratings, indicating a lack of strong bullish conviction among sell-side professionals who may view the current valuation or growth outlook as adequate rather than exceptional.
ResMed Inc. has experienced a significant decline in its average analyst price target over the past year, dropping from $299.27 in early 2026 to $240.31 in September 2026, reflecting a downward revision in expectations for the company's future earnings potential or market position.
Short interest in the stock has increased to 12,794,915 shares as of August 14, 2026, representing approximately 8.93% of the float, which indicates that a notable portion of the market is betting against the stock's performance, potentially creating downward pressure on the share price.
Despite the recent dividend increase, the company's payout ratio stands at 25.31%, and with a P/E ratio of 21.88, investors may question whether the current valuation is justified given the slowing growth in analyst price targets and the presence of legal investigations, making the risk-reward profile less attractive compared to other healthcare stocks.

RMD Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $240.31, with a high forecast of $300.00 and a low forecast of $213.00.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 10 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMD, but not buy additional shares or sell existing shares.

According to analysts, ResMed's stock has a predicted upside of 8.49% based on their 12-month stock forecasts.

Over the previous 90 days, ResMed's stock had 3 downgrades and 1 upgrade by analysts.

ResMed has been rated by research analysts at Citigroup, Jefferies Financial Group, KeyCorp, Mizuho, Morgan Stanley, Piper Sandler, Robert W. Baird, Rothschild & Co Redburn, Royal Bank Of Canada, The Goldman Sachs Group, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like ResMed more than other "healthcare" companies. The consensus rating score for ResMed is 2.38 while the average consensus rating score for "healthcare" companies is 2.30. Learn more on how RMD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With ResMed Recommendations

MarketBeat monitors more than a dozen sources for ResMed analyst ratings, with the most recent rating issued on 8/31/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ResMed (RMD) Stock Forecast & Price Target